Glanzmann's thrombasthenia (GT) is an autosomal recessive inherited bleeding disorder due to a defect in platelet function. The hallmark of this disease is severely reduced/absent platelet aggregation in response to multiple physiological agonists. Bleeding signs in GT include epistaxis, bruising, gingival hemorrhage, gastrointestinal hemorrhage, hematuria, menorrhagia, and hemarthrosis. Homozygous or compound heterozygous mutations in the genes of GPIIb and GPIIIa lead to GT. A patient with GT, with no possible causative mutations in GPIIb and GPIIIa genes, may harbor defects in a regulatory element affecting the transcription of these 2 genes. GT occurs in high frequency in certain ethnic populations with an increased incidence of consanguinity such as in Indians, Iranians, Iraqi Jews, Palestinian and Jordanian Arabs, and French Gypsies. Carrier detection in GT is important to control the disorder in family members. Carrier detection can be done both by protein analysis and direct gene analysis.
French DLThe molecular genetics of Glanzmann's thrombasthenia. Platelets . 1998;9:5-20.
3.
Nurden AT, Caen JPAn abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia . Br J Haematol. 1974;28:253-260.
4.
Phillips DR, Jenkins CS, Luscher EF, Larrieu M.Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature. 1975;257:599-600.
5.
Coller BS, Seligsohn U., West SM, Scudder LE, Norton KJPlatelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb/IIIA and alpha v beta 3 integrins in platelet protein trafficking. Blood. 1991;78:2603-2610.
6.
Perutelli P. , Mori PGBiochemical and molecular basis of Glanzmann's thrombasthenia. Haematologica. 1992;77:421-426.
7.
Poncz M., Rifat S., Coller BS, et al. Glanzmann thrombasthenia secondary to a Gly273->Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb . J Clin Invest. 1994;93:172-179.
8.
Nurden AT, George JNInherited abnormalities of the platelet membrane: Glanzmann's Thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis, Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:921-943.
9.
George JN, Caen JP, Nurden ATGlanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383-1395.
10.
French DL, Seligsohn U.Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia . Arterioscler Thromb Vasc Biol. 2000;20:607-610.
11.
Zucker MB, Pert JH, Hilgartner MWPlatelet function in a patient with thrombasthenia. Blood . 1966;28:524-534.
12.
Harrison P. , Wilbourn B., Debili N., et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest. 1989;84: 1320-1324.
13.
Handagama P. , Rappolee DA, Werb Z., Levin J., Bainton DFPlatelet alpha-granule fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse megakaryocytes. J Clin Invest.1990;86: 1364-1368.
14.
Peerschke EIMaintenance of GPIIb-IIIa avidity supporting ``irreversible'' fibrinogen binding is energy-dependent. J Lab Clin Med. 1999;134:398-404.
15.
Legrand C., Dubernard V., Nurden ATStudies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood. 1989;73: 1226-1234.
16.
Weiss HJ, Hawiger J., Ruggeri ZM, Turitto VT, Thiagarajan P., Hoffmann T.Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate . J Clin Invest. 1989;83:288-297.
17.
Bevers EM, Comfurius P., Nieuwenhuis HK, et al. Platelet prothrombin converting activity in hereditary disorders of platelet function. Br J Haematol. 1986;63:335-345.
18.
Weiss HJ, Turitto VT, Baumgartner HRRole of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects . J Clin Invest.1986;78:1072-1082.
19.
Weiss HJ, Lages B.Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity-a comparison with Scott syndrome. Blood. 1997;89:1599-1611.
20.
Holme PA, Solum NO, Brosstad F., Egberg N., Lindahl TLStimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa. Thromb Haemost.1995;74: 1533-1540.
21.
Cohen I., Glaser T., Seligsohn U.Effects of ADP and ATP on bovine fibrinogen- and ristocetin-induced platelet aggregation in Glanzmann's thrombasthenia. Br J Haematol . 1975;31:343-347.
22.
Caen JP, Cronberg S., Levy-Toledano S., Kubisz P., Pinkhas JPNew data on Glanzmann's thrombasthenia. Proc Soc Exp Biol Med. 1971;136:1082-1086.
23.
Hagen I., Nurden A., Bjerrum OJ, Solum NO, Caen J.Immunochemical evidence for protein abnormalities in platelets from patients with Glanzmann's thrombasthenia and Bernard-Soulier syndrome. J Clin Invest. 1980;65:722-731.
24.
Nurden AT, Didry D., Kieffer N., McEver RPResidual amounts of glycoproteins IIb and IIIa may be present in the platelets of most patients with Glanzmann's thrombasthenia. Blood. 1985;65:1021-1024.
25.
Seligsohn U. , Coller BS, Zivelin A., Plow EF, Ginsberg MHImmunoblot analysis of platelet glycoprotein IIb in patients with Glanzmann thrombasthenia in Israel. Br J Haematol. 1989;72:415-423.
26.
Boudreaux MK , Lipscomb DLClinical, biochemical, and molecular aspects of Glanzmann's thrombasthenia in humans and dogs. Vet Pathol . 2001;38:249-260.
27.
Coller BSPlatelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics . J Clin Invest. 1997;99: 1467-1471.
28.
French DL, Coller BSHematologically important mutations: Glanzmann thrombasthenia. Blood Cells Mol Dis. 1997;23:39-51.
29.
Basani RB, French DL, Vilaire G., et al. A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3. Blood. 2000;95:180-188.
30.
Basani RB, Vilaire G., Shattil SJ, Kolodziej MA, Bennett JS, Poncz M.Glanzmann thrombasthenia due to a 2 amino acid deletion in the fourth calcium-binding domain of alpha IIb: demonstration of the importance of calcium-binding domains in the conformation of alpha IIb beta 3. Blood. 1996;88:167-173.
31.
Tozer EC, Liddington RC, Sutcliffe MJ, Smeeton AH, Loftus JCLigand binding to integrin alphaIIbbeta3 is dependent on a MIDAS-like domain in the beta3 subunit. J Biol Chem. 1996;271:21978-21984.
32.
Ginsberg MH, Frelinger AL, Lam SC, et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood. 1990;76:2017-2023.
33.
Jung SM, Yoshida N., Aoki N., Tanoue K., Yamazaki H., Moroi M.Thrombasthenia with an abnormal platelet membrane glycoprotein IIb of different molecular weight. Blood. 1988 ;71:915-922.
Ginsberg MH , Lightsey A., Kunicki TJ, Kaufmann A., Marguerie G., Plow EFDivalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia . J Clin Invest.1986;78:1103-1111.
36.
Rosenberg N. , Hauschner H., Peretz H., et al. A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3: 2764-2772.
37.
Schlegel N. , Gayet O., Morel-Kopp MC, et al. The molecular genetic basis of Glanzmann's thrombasthenia in a gypsy population in France: identification of a new mutation on the alpha IIb gene. Blood . 1995;86: 977-982.
38.
Yasunaga K. , Nomura S.Statistical analysis of Glanzmann's thrombasthenia in Japan. Acta Haematol. 1993 ;89:165-166.
39.
Rosenberg N. , Yatuv R., Orion Y., et al. Glanzmann thrombasthenia caused by an 11.2-kb deletion in the glycoprotein IIIa (beta3) is a second mutation in Iraqi Jews that stemmed from a distinct founder. Blood . 1997;89:3654-3662.
Toogeh G., Sharifian R., Lak M., Safaee R., Artoni A., Peyvandi F.Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004 ;77:198-199.
42.
Springer TAFolding of the N-terminal,ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci U S A. 1997;94:65-72.
43.
Peretz H., Rosenberg N., Landau M., et al. Molecular diversity of Glanzmann thrombasthenia in southern India: new insights into mRNA splicing and structure-function correlations of alphaIIbbeta3 integrin (ITGA2B, ITGB3). Hum Mutat. 2006;27:359-369.
44.
D'Andrea G. , Colaizzo D., Vecchione G., Grandone E., Di Minno G., Margaglione M.GLAnzmann's Thrombasthenia Italian Team (GLATIT).Glanzmann's thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost.2002;87:1034-1042.
45.
Nelson EJ, Nair SC, Peretz H., et al. Diversity of Glanzmann thrombasthenia in southern India: 10 novel mutations identified among 15 unrelated patients. J Thromb Haemost. 2006;4:1730-1737.
46.
Ambo H., Kamata T., Handa M., et al. Novel point mutations in the alphaIIb subunit (Phe289->Ser, Glu324->Lys and Gln747->Pro) causing thrombasthenic phenotypes in four Japanese patients. Br J Haematol. 1998;102:829-840.
47.
Ferrer M., Fernandez-Pinel M., Gonzalez-Manchon C., Gonzalez J., Ayuso MS, Parrilla R.A mutant (Arg327- >His) GPIIb associated to thrombasthenia exerts a dominant negative effect in stably transfected CHO cells. Thromb Haemost. 1996;76:292-301.
48.
Frischmeyer PA, Dietz HCNonsense-mediated mRNA decay in health and disease. Hum Mol Genet. 1999;8:1893-1900.
49.
Gu JM, Xu WF, Wang XD, Wu QY, Chi CW, Ruan CGIdentification of a nonsense mutation at amino acid 584-arginine of platelet glycoprotein IIb in patients with type I Glanzmann thrombasthenia. Br J Haematol. 1993;83:442-449.
50.
Iwamoto S., Nishiumi E., Kajii E., Ikemoto S.An exon 28 mutation resulting in alternative splicing of the glycoprotein IIb transcript and Glanzmann's thrombasthenia. Blood. 1994;83:1017-1023.
51.
Peretz H., Rosenberg N., Usher S., et al. Glanzmann's thrombasthenia associated with deletion-insertion and alternative splicing in the glycoprotein IIb gene. Blood . 1995;85:414-420.
52.
Burk CD, Newman PJ, Lyman S., Gill J., Coller BS, Poncz M.A deletion in the gene for glycoprotein IIb associated with Glanzmann's thrombasthenia . J Clin Invest. 1991;87:270-276.
53.
Newman PJ, Seligsohn U., Lyman S., Coller BSThe molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A. 1991;88:3160-3164.
54.
Coller BS, French DLHereditary qualitative platelet disorders. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams' Hematology. 6th ed. New York, NY: McGraw Hill; 2001:1551-1581.
55.
Nelson EJ, Li J., Mitchell WB, Chandy M., Srivastava A., Coller BSThree novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. J Thromb Haemost. 2005;3:2773-2783.
56.
Vinciguerra C., Trzeciak MC, Philippe N., et al. Molecular study of Glanzmann thrombasthenia in 3 patients issued from 2 different families . Thromb Haemost . 1995;74:822-827.
57.
Ferrer M., Tao J., Iruin G., et al. Truncation of glycoprotein (GP) IIIa (616-762) prevents complex formation with GPIIb: novel mutation in exon 11 of GPIIIa associated with thrombasthenia. Blood. 1998;92:4712-4720.
58.
Morel-Kopp MC , Kaplan C., Proulle V., et al. A three amino acid deletion in glycoprotein IIIa is responsible for type I Glanzmann's thrombasthenia: importance of residues Ile325Pro326Gly327 for beta3 integrin subunit association . Blood. 1997;90:669-677.
59.
Simsek S., Heyboer H., De Bruijne-Admiraal LG, Goldschmeding R., Cuijpers HT, von dem Borne AEGlanzmann's thrombasthenia caused by homozygosity for a splice defect that leads to deletion of the first coding exon of the glycoprotein IIIa mRNA . Blood. 1993;81:2044-2049.
60.
Xie J., Pabon D., Jayo A., Butta N., Gonzalez-Manchon C.Type I Glanzmann thrombasthenia caused by an apparently silent beta3 mutation that results in aberrant splicing and reduced beta3 mRNA. Thromb Haemost. 2005;93:897-903.
61.
Li L., Bray PFHomologous recombination among three intragene Alu sequences causes an inversion-deletion resulting in the hereditary bleeding disorder Glanzmann thrombasthenia. Am J Hum Genet. 1993;53:140-149.
62.
Bajt ML, Loftus JCMutation of a ligand binding domain of beta 3 integrin. Integral role of oxygenated residues in alpha IIb beta 3 (GPIIb-IIIa) receptor function . J Biol Chem.1994;269:20913-20919.
63.
Nair S., Ghosh K., Shetty S., Mohanty D.A novel Ser123Pro substitution in the MIDAS domain of integrin 3 associated with variant Glanzmann's thrombasthenia in an Indian patient. Haematologica. 2004;89:1529-1530.
64.
Calvete JJ, Henschen A., Gonzalez-Rodriguez J.Assignment of disulphide bonds in human platelet GPIIIa. A disulphide pattern for the beta-subunits of the integrin family. Biochem J.1991;274(Pt 1):63-71.
65.
Grimaldi CM , Chen F., Scudder LE, Coller BS, French DLA Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia . Blood. 1996;88:1666-1675.
66.
Sun QH, Liu CY, Wang R., Paddock C., Newman PJDisruption of the long-range GPIIIa Cys(5)-Cys(435) disulfide bond results in the production of constitutively active GPIIb-IIIa (alpha(IIb)beta(3)) integrin complexes. Blood. 2002;100:2094-2101.
67.
Ylanne J., Huuskonen J., O'Toole TE, Ginsberg MH, Virtanen I., Gahmberg CGMutation of the cytoplasmic domain of the integrin beta 3 subunit. Differential effects on cell spreading, recruitment to adhesion plaques, endocytosis, and phagocytosis. J Biol Chem.1995;270:9550-9557.
68.
Bray PF, Rosa JP, Lingappa VR, Kan YW, McEver RP, Shuman MABiogenesis of the platelet receptor for fibrinogen: evidence for separate precursors for glycoproteins IIb and IIIa. Proc Natl Acad Sci U S A. 1986;83:1480-1484.
Vinciguerra C., Bordet JC, Beaune G., Grenier C., Dechavanne M., Negrier C.Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) and glycoprotein IIIa (beta3) genes. Platelets. 2001;12:486-495.
71.
Phillips R. , Richards M.Venous thrombosis in Glanzmann's hrombasthenia . Haemophilia. 2007;13:758-759.
72.
Ten Cate H. , Brandjes DP, Smits PH, van Mourik JAThe role of platelets in venous thrombosis: a patient with Glanzmann's thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. J Thromb Haemost. 2003;1:394-395.
73.
Ghosh K., Kulkarni B., Nair S., Shetty S., Mohanty D.Human platelet alloantigen polymorphism in Glanzmann's thrombasthenia and its impact on the severity of the disease. Br J Haematol.2002;119:348-353.
74.
Kunicki TJ, Pidard D., Cazenave JP, Nurden AT, Caen JPInheritance of the human platelet alloantigen, PlA1, in type I Glanzmann's thrombasthenia. J Clin Invest. 1981;67:717-724.
75.
Jennings LK , Ashmun RA, Wang WC, Dockter MEAnalysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry. Blood. 1986;68:173-179.
Ruan C., Gu J., Wang X., Chu X., Pan J.Application of GPIIIa gene Taq I polymorphism to determination of carrier status in Glanzmann's thrombasthenia families of Chinese origin. Thromb Haemost. 1993;69:64-69.
78.
Coller BS, Seligsohn U., Zivelin A., Zwang E., Lusky A., Modan M.Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations of Israel: comparison of techniques for carrier detection. Br J Haematol . 1986;62:723-735.
79.
Srivastava A., Usher S., Nelson EJ, et al. Prenatal diagnosis of Glanzmann thrombasthenia . Natl Med J India. 2003;16:207-208.
80.
Bellucci S. , Caen J.Molecular basis of Glanzmann's thrombasthenia and current strategies in treatment. Blood Rev. 2002;16:193-202.
81.
Zotz RB, Scharf RERecombinant factor VIIa in patients with platelet function disorders or thrombocytopenia . Hamostaseologie. 2007 ;27:251-262.
82.
Tengborn L. , Petruson B.A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost. 1996;75: 981-982.
83.
Valentino LAUse of rFVIIa in 4 children with Glanzmann thrombasthenia . J Pediatr Hematol Oncol. 2006;28:653-658.
